AbCellera: From UBC Lab to Global Biotech Powerhouse

From a Campus Project to a Global Player

AbCellera began as a small spin-off from the University of British Columbia in 2012, created by a group of alumni eager to apply advanced antibody discovery technologies. What started as a project in an academic lab soon evolved into a pioneering biotechnology enterprise.

The company leveraged deep scientific expertise and cutting-edge tools to speed up the identification and development of antibody therapies. This innovation has placed AbCellera at the forefront of biotechnology, contributing significantly to British Columbia’s growing life sciences sector.

Driving Innovation in Biotechnology

AbCellera’s technology platform accelerates the discovery of antibodies used in developing new therapeutics. Its approach combines automation, artificial intelligence, and microfluidics to analyze immune responses at unprecedented speed.

Such capabilities attracted collaborations with major pharmaceutical companies and positioned AbCellera as a strategic partner in global efforts to combat disease, including during health crises like the COVID-19 pandemic.

Economic and Academic Impact

The company’s growth underscores the success of university-based entrepreneurship and its value to regional economies. AbCellera has become a major employer in Vancouver’s tech and biotech ecosystem, while maintaining strong research ties with UBC, fostering innovation and talent development in the province.

"It didn't look like the beginning of a global biotech company," said one of the founders, reflecting on the company’s early days in a modest lab space.

Building the Future of Therapeutics

AbCellera continues to expand its capabilities, investing in infrastructure and new research partnerships. Its story reflects how scientific discovery, entrepreneurial vision, and academic collaboration can shape a world-class biotechnology company from the ground up.


Author’s summary:
AbCellera’s journey from a UBC research project to a worldwide biotech leader showcases how academic innovation and entrepreneurial drive fuel biotech progress and economic growth.

more

Mirage News Mirage News — 2025-11-26

More News